UPMC, Helomics Join to Develop Predictive Models of Ovarian Cancer Outcomes

UPMC, Helomics Join to Develop Predictive Models of Ovarian Cancer Outcomes
Researchers from the University of Pittsburgh Medical Center (UPMC) have teamed up with Helomics — a subsidiary of Predictive Oncology — to explore the use of artificial intelligence as a way to improve the treatment decision process for ovarian cancer. Despite the advances made to improve diagnosis and treatment, few prognostic tools are accurate enough to predict outcomes in these patients. This results in high recurrence rates and poor overall survival. The collaborative study is taking advantage of Helomics’ artificial intelligence (AI) D-CHIP platform to predict patients' responses to therapy and build a roadmap for personalized treatment. “We believe that this effort will enhance our understanding of the molecular profiles of women with ovarian cancer by using the power of artificial intelligence to create predictive models of therapeutic success,” Robert Edwards, MD, professor and chair of the department of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh School of Medicine, said in a press release. “We are excited about the potential for AI-powered, evidence-based decision making to increase our ability to bring about successful outcomes,” said Edwards, who is also co-leader of the Breast and Ovarian Cancer Program at the UPMC Hillman Cancer Center. The AI approach will combine genetic information from each patient with their responses to ther
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *